These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29101798)

  • 1. Cytokine serum levels remain unchanged during lithium augmentation of antidepressants in major depression.
    Ricken R; Busche M; Schlattmann P; Himmerich H; Bopp S; Bschor T; Richter C; Stamm TJ; Heinz A; Hellweg R; Lang UE; Adli M
    J Psychiatr Res; 2018 Jan; 96():203-208. PubMed ID: 29101798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain-derived neurotrophic factor serum concentrations in acute depressive patients increase during lithium augmentation of antidepressants.
    Ricken R; Adli M; Lange C; Krusche E; Stamm TJ; Gaus S; Koehler S; Nase S; Bschor T; Richter C; Steinacher B; Heinz A; Rapp MA; Borgwardt S; Hellweg R; Lang UE
    J Clin Psychopharmacol; 2013 Dec; 33(6):806-9. PubMed ID: 24018547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
    Park M; Newman LE; Gold PW; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
    J Psychiatr Res; 2017 Jan; 84():113-118. PubMed ID: 27718369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ghrelin Serum Concentrations Are Associated with Treatment Response During Lithium Augmentation of Antidepressants.
    Ricken R; Bopp S; Schlattmann P; Himmerich H; Bschor T; Richter C; Elstner S; Stamm TJ; Schulz-Ratei B; Lingesleben A; Reischies FM; Sterzer P; Borgwardt S; Bauer M; Heinz A; Hellweg R; Lang UE; Adli M
    Int J Neuropsychopharmacol; 2017 Sep; 20(9):692-697. PubMed ID: 28911006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder.
    Bauer M; Dell'osso L; Kasper S; Pitchot W; Dencker Vansvik E; Köhler J; Jørgensen L; Montgomery SA
    J Affect Disord; 2013 Oct; 151(1):209-19. PubMed ID: 23810357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melancholic and atypical major depression--connection between cytokines, psychopathology and treatment.
    Dunjic-Kostic B; Ivkovic M; Radonjic NV; Petronijevic ND; Pantovic M; Damjanovic A; Poznanovic ST; Jovanovic A; Nikolic T; Jasovic-Gasic M
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jun; 43():1-6. PubMed ID: 23200828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study.
    Dold M; Bartova L; Kautzky A; Serretti A; Porcelli S; Souery D; Mendlewicz J; Montgomery S; Zohar J; Kasper S
    Eur Neuropsychopharmacol; 2018 Dec; 28(12):1305-1313. PubMed ID: 30446357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery.
    Dahl J; Ormstad H; Aass HC; Malt UF; Bendz LT; Sandvik L; Brundin L; Andreassen OA
    Psychoneuroendocrinology; 2014 Jul; 45():77-86. PubMed ID: 24845179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
    Kagawa S; Mihara K; Suzuki T; Nagai G; Nakamura A; Nemoto K; Kondo T
    Neuropsychobiology; 2017; 75(3):145-150. PubMed ID: 29332095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder.
    Chen CY; Yeh YW; Kuo SC; Liang CS; Ho PS; Huang CC; Yen CH; Shyu JF; Lu RB; Huang SY
    Psychoneuroendocrinology; 2018 Jan; 87():108-118. PubMed ID: 29055264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro- and anti-inflammatory cytokines, but not CRP, are inversely correlated with severity and symptoms of major depression.
    Schmidt FM; Schröder T; Kirkby KC; Sander C; Suslow T; Holdt LM; Teupser D; Hegerl U; Himmerich H
    Psychiatry Res; 2016 May; 239():85-91. PubMed ID: 27137966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds.
    Fornaro M; Rocchi G; Escelsior A; Contini P; Martino M
    J Affect Disord; 2013 Mar; 145(3):300-7. PubMed ID: 22981313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment response of lithium augmentation in geriatric compared to non-geriatric patients with treatment-resistant depression.
    Buspavanich P; Behr J; Stamm T; Schlattmann P; Bschor T; Richter C; Hellweg R; Heinz A; Berger M; Hindinger C; Rentzsch J; de Millas W; Jockers-Scherübl MC; Bräunig P; Adli M; Ricken R
    J Affect Disord; 2019 May; 251():136-140. PubMed ID: 30921597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.
    Yang JJ; Wang N; Yang C; Shi JY; Yu HY; Hashimoto K
    Biol Psychiatry; 2015 Feb; 77(3):e19-e20. PubMed ID: 25104172
    [No Abstract]   [Full Text] [Related]  

  • 15. Changes in the serum levels of inflammatory cytokines in antidepressant drug-naïve patients with major depression.
    Zou W; Feng R; Yang Y
    PLoS One; 2018; 13(6):e0197267. PubMed ID: 29856741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression.
    Nelson JC; Baumann P; Delucchi K; Joffe R; Katona C
    J Affect Disord; 2014 Oct; 168():269-75. PubMed ID: 25069082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrocardiographic Changes During Initiation of Lithium Augmentation of Antidepressant Pharmacotherapy.
    Berger M; Kermer J; Behr J; Schulz-Menger J; Bilal S; Osterland SL; O'Malley G; Bschor T; Schlattmann P; Stamm T; Steinacher B; de Millas W; Richter C; Heinz A; Adli M; Buspavanich P; Ricken R
    J Clin Psychopharmacol; 2022 Jan-Feb 01; 42(1):87-91. PubMed ID: 34854829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants.
    Bauer M; Adli M; Bschor T; Pilhatsch M; Pfennig A; Sasse J; Schmid R; Lewitzka U
    Neuropsychobiology; 2010; 62(1):36-42. PubMed ID: 20453533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in serum concentrations and in cytokine production by blood cell cultures of a patient with major depression--case report.
    Dubas-Slemp H; Kamińska T; Marmurowska-Michałowska H; Kandefer-Szerszeń M
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):496-504. PubMed ID: 12898886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment-resistant major depressive disorder.
    Yamasaki K; Hasegawa T; Takeda M
    Neuropsychopharmacol Rep; 2020 Jun; 40(2):130-137. PubMed ID: 32162496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.